Climb Bio Inc. (CLYM)
Climb Bio Inc. (CLYM) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 9.05 |
| Marktkapitalisierung | 1 Mrd |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -57.62 Mio |
| Beta | 0.08 |
| EPS (ttm) | -0.82 |
| KGV (TTM) | n/a |
| Forward-KGV | -16.52 |
| KBV (TTM) | 4.18 |
| KUV (TTM) | n/a |
| Earnings Date | Aug 14, 2025 |
| Brief | 16.06 |
| Volumen | 980,703 |
| Ø Vol. (20D) | 1,309,325 |
| Eröffnung | 16.90 |
| Vortagesschluss | 17.44 |
| Tagesspanne | 16.46 - 17.53 |
| 52-Wk Range | 1.54 - 17.53 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; a...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Climb Bio 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -59.85 Mio, ein Rückgang von -19.01 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Insider Monkey
Climb Bio (CLYM) Enters Agreement for $110M Private Placement FinancingClimb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement ...
